Upgrade to FLUIfort syrup (carbocysteine lysine salt monohydrate) ? for secretory diseases of the respiratory tract
Not just ANY carbocysteine syrup!
Mucoactive pharmaceuticals are widely utilized in Europe. Their therapeutic value as a coadjuvant in treatment of secretory diseases of the respiratory tract has been well established by various studies.
The addition of the lysine salt to the basic S-carboxymethylcysteine moiety leads to an ENHANCED ABSORPTION of the principal active ingredient leaving intact the characteristics of clinical efficacy1. This is what makes FLUIfort syrup uniquely different from other basic carbocysteine syrups.
: Improved eradication and clinical recovery in 5 days of associated therapy with an antibiotic2
: A shortening of antibiotic treatment course3
: A prevention of chronic bronchitis relapse3
FLUIfort normalizes mucous secretion and increases fluidity and viscosity in acute and chronic affections of the respiratory apparatus.
Dosage and Method of Administration:
FLUIfort syrup is supplied with a dosage cap with measurement scales corresponding to 2.5, 5 10 and 15ml.
Adults: 15ml 2 ? 3 times per day
Children: > 5 years old: 5ml 2 ? 3 times daily
1 ? 5 years old: 2.5ml 2 ? 3 times daily
FLUIfort is available from pharmacies as cherry flavoured syrup in 200ml bottles containing 9% carbocysteine lysine salt monohydrate.
Further information: Collis Williams Tel: 244 847, 224 104
1.Braga PC, Borsa M, De Angelis L, Bossi R, Allegra L, Scaglione F,Scarpazza G. Pharmacokinetic behaviour of S-carboxymethylcysteine-Lys in patients with chronic bronchitis. Clin Ther 1982:v4, n6:480-488
2.Sevieri GF, British Medical Journal Italian Edition, vol.13, December 1990
3.Allegra L, Cordaro Cl, Grassi C, Respiration: 63:174-180,1996